Suppliers and packagers for generic pharmaceutical drug: hexaminolevulinate hydrochloride

hexaminolevulinate hydrochloride

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555	NDA	Photocure Inc.	10511-3001-2	1 KIT in 1 CARTON (10511-3001-2) * 50 mL in 1 SYRINGE, PLASTIC * 50 mL in 1 VIAL, GLASS	2018-05-01

Hexamvinolevulinate Hydrochloride Suppliers Analysis

Last updated: February 19, 2026

This report analyzes key suppliers for hexaminolevulinate hydrochloride, a photosensitizing agent used in photodynamic therapy. It details manufacturing capabilities, regulatory compliance, and capacity to inform pharmaceutical R&D and investment decisions.

Who Are the Primary Manufacturers of Hexamvinolevulinate Hydrochloride?

Several entities manufacture hexaminolevulinate hydrochloride, with production capabilities varying in scale and regulatory adherence. Key players include established pharmaceutical chemical manufacturers and specialized API producers.

Key Manufacturers and Their Capabilities:

• Novartis AG: While primarily known as a pharmaceutical company utilizing hexaminolevulinate hydrochloride (under the brand name Gleolan) in its medical devices and treatments, Novartis oversees a significant portion of the supply chain through its internal manufacturing and contracted production. Their focus is on Good Manufacturing Practice (GMP) compliant production for finished drug products.
• Asahi Kasei Pharma Corporation: This Japanese pharmaceutical company is a significant player in the development and manufacturing of active pharmaceutical ingredients (APIs), including those for photosensitizing agents. Their involvement suggests adherence to stringent Japanese and international regulatory standards.
• Specialty Chemical Manufacturers: A segment of specialized chemical manufacturers produces hexaminolevulinate hydrochloride as an API or intermediate for broader pharmaceutical applications. These suppliers often operate with a focus on custom synthesis and bulk production. Identifying specific entities within this category requires detailed market intelligence due to the proprietary nature of their client relationships. Examples of potential suppliers with relevant expertise include companies with strong backgrounds in porphyrin synthesis or heterocyclic chemistry.

Table 1: Overview of Key Hexamvinolevulinate Hydrochloride Stakeholders

Entity Type	Primary Role	Manufacturing Focus	Regulatory Standing
Pharmaceutical Companies	Finished drug product formulation, distribution, and market access	GMP-compliant formulation of hexaminolevulinate hydrochloride into marketable therapies	FDA (US), EMA (EU), PMDA (Japan) approved drug products
API Manufacturers	Synthesis and purification of hexaminolevulinate hydrochloride API	Bulk API production meeting pharmacopoeial standards (e.g., USP, EP)	GMP certification, potential FDA/EMA/PMDA inspections, Drug Master File (DMF) submission
Specialty Chemical Suppliers	Contract manufacturing, custom synthesis, intermediate production	Variable, from research-grade to pilot-scale, with potential for commercial scale	Quality control systems, ISO certification, adherence to client-specific quality agreements

What Are the Regulatory Requirements for Hexamvinolevulinate Hydrochloride Production?

Production of hexaminolevulinate hydrochloride intended for pharmaceutical use is subject to rigorous regulatory oversight to ensure safety, efficacy, and quality. This applies to both the API and the finished drug product.

Key Regulatory Frameworks and Standards:

• Good Manufacturing Practice (GMP): Manufacturers must adhere to GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. GMP ensures that products are consistently produced and controlled according to quality standards appropriate for their intended use.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities. A DMF contains confidential, detailed information about the facilities, processes, and materials used in the manufacturing, processing, packaging, and storing of a drug. This allows regulatory agencies to review the API information independently while protecting proprietary manufacturing details.
• Pharmacopoeial Standards: Hexamvinolevulinate hydrochloride must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP). These monographs define the identity, strength, quality, and purity characteristics of the drug substance.
• International Conference on Harmonisation (ICH) Guidelines: Manufacturers follow ICH guidelines for quality, safety, efficacy, and multidisciplinary aspects of pharmaceutical development and registration. Relevant guidelines include those on impurity testing (ICH Q3A, Q3B), stability testing (ICH Q1A), and pharmaceutical quality systems (ICH Q10).
• Specific Country Regulations: Beyond these general frameworks, manufacturers must comply with the specific drug registration and manufacturing requirements of each target market. This includes obtaining marketing authorization for the finished drug product.

Table 2: Key Regulatory Compliance Aspects for Hexamvinolevulinate Hydrochloride Suppliers

Regulatory Aspect	Description	Impact on Suppliers
GMP Compliance	Mandated by FDA, EMA, PMDA, etc. Ensures consistent quality and control throughout the manufacturing process.	Requires robust quality management systems, validated processes, qualified equipment, trained personnel, and detailed documentation. Regular inspections are standard.
Drug Master File (DMF)	Confidential document submitted to regulatory agencies detailing API manufacturing.	Facilitates API approval by referencing the DMF in a drug product application. Requires meticulous record-keeping and data integrity.
Pharmacopoeial Standards	Monographs in USP, EP, JP define required purity, potency, and other quality attributes.	API must consistently meet these predefined chemical and physical specifications. Analytical testing is critical.
Impurity Profiling	ICH Q3A/Q3B guidelines require identification, qualification, and control of impurities.	Requires sophisticated analytical techniques (e.g., HPLC, GC-MS) to detect and quantify process-related impurities and degradation products. Development of control strategies is essential.
Stability Testing	ICH Q1A guidelines for assessing drug substance stability under various storage conditions.	Manufacturers must conduct long-term, intermediate, and accelerated stability studies to establish shelf-life and recommended storage conditions.
Change Control	Processes for managing any changes to manufacturing processes, materials, or facilities.	Requires a formal system to evaluate, approve, and document all proposed changes, assessing their potential impact on product quality and regulatory filings.

What Is the Production Capacity and Scalability of Key Suppliers?

Understanding the production capacity and scalability of hexaminolevulinate hydrochloride suppliers is crucial for assessing supply chain reliability and supporting market growth.

Factors Influencing Capacity and Scalability:

• Existing Infrastructure: The availability of dedicated manufacturing suites, reaction vessels, purification equipment, and quality control laboratories.
• Synthetic Route Complexity: The number of steps, efficiency of reactions, and availability of key starting materials and reagents influence batch size and throughput.
• Regulatory Status: GMP-compliant facilities often have higher operational costs and longer lead times due to stringent process validation and documentation requirements.
• Supply Chain Integration: The ability to secure reliable sources of raw materials and intermediates.
• Process Optimization: Continuous efforts to improve reaction yields, reduce cycle times, and enhance purification efficiency.

Assessing Scalability:

Scalability for hexaminolevulinate hydrochloride involves the ability to increase production volume to meet growing demand. This can be achieved through:

• Expanding existing facilities: Increasing the footprint of manufacturing plants.
• Adding new production lines: Investing in additional equipment and personnel.
• Process intensification: Implementing continuous manufacturing or advanced batch processing techniques.
• Strategic partnerships and contract manufacturing: Leveraging external manufacturing capabilities.

Given that hexaminolevulinate hydrochloride is used in specific oncological treatments (e.g., for glioblastoma), its market volume, while critical for patients, is not comparable to blockbuster drugs. Therefore, suppliers typically maintain flexible capacities that can be scaled up based on demand forecasts and clinical trial expansions. Larger, vertically integrated pharmaceutical companies or established API manufacturers are generally better positioned for significant scalability due to their access to capital and existing infrastructure.

Table 3: Production Capacity and Scalability Considerations

Supplier Type	Typical Production Scale	Scalability Potential	Key Determinants of Scalability
Major Pharmaceutical Companies (Internal)	Kilograms to Metric Tons	High, due to access to capital, extensive manufacturing networks, and established process development teams.	Investment in expanded GMP facilities, dedicated R&D for process optimization, long-term supply chain agreements.
Dedicated API Manufacturers	Kilograms to Metric Tons	Moderate to High, depending on facility size, specialization, and investment in versatile production equipment.	Availability of suitable reaction vessels, efficient purification technologies, and robust quality control systems.
Specialty Chemical/Contract Manufacturers	Grams to Kilograms (initially)	Variable. Can scale to metric tons if equipped and certified. Scalability is often tied to the client's demand and the contract.	Flexibility of equipment, adherence to client-specific quality agreements, ability to secure raw materials for larger batches.

What Are the Key Differentiators Among Hexamvinolevulinate Hydrochloride Suppliers?

Suppliers of hexaminolevulinate hydrochloride differentiate themselves through a combination of product quality, regulatory standing, manufacturing expertise, and customer service.

Differentiating Factors:

• API Purity and Impurity Profile: Consistently achieving high purity levels and a well-characterized, controlled impurity profile is paramount. Manufacturers with robust analytical capabilities and a strong understanding of degradation pathways gain a competitive edge.
• Regulatory Track Record: A history of successful regulatory submissions and inspections (FDA, EMA, PMDA) builds confidence for pharmaceutical clients. Suppliers with existing DMFs for hexaminolevulinate hydrochloride or related compounds are favorably positioned.
• Manufacturing Process Robustness and Yield: Optimized, validated, and scalable synthetic routes that deliver consistent yields are crucial for cost-effectiveness and reliable supply.
• Supply Chain Security and Redundancy: The ability to ensure a stable supply of critical raw materials and to manage production risks through redundancies or multiple manufacturing sites.
• Technical Support and Collaboration: Providing in-depth technical expertise, assisting with formulation challenges, and engaging in collaborative process development can be significant differentiators.
• Lead Times and Flexibility: Responsiveness to orders, ability to accommodate varying batch sizes, and transparent communication regarding production timelines.
• Cost Competitiveness: While quality and reliability are primary, competitive pricing remains a key consideration, especially for generic or biosimilar development.

Table 4: Supplier Differentiation Matrix

Supplier Aspect	High Performer Differentiator	Standard Performer
API Quality & Purity	Consistently achieves >99.5% purity. Well-defined and controlled impurity profile (e.g., individual impurities <0.1%). Robust analytical validation.	Achieves specified pharmacopoeial purity. Impurity profile generally within acceptable limits but may require client-specific control.
Regulatory Compliance	Multiple successful DMF filings accepted by major agencies (FDA, EMA). Strong audit history. Experience with Type II DMFs.	Basic DMFs filed. May have passed some agency inspections. Regulatory support may be limited to providing standard documentation.
Manufacturing Expertise	Patented or proprietary synthetic routes leading to higher yields and lower costs. Expertise in complex chiral synthesis or heterocyclic chemistry.	Standard, published synthetic routes. Competent process control.
Supply Chain Reliability	Dual sourcing for critical raw materials. Robust risk mitigation plans. Transparent supply chain mapping.	Single sourcing for some materials. Basic business continuity plans.
Technical Collaboration	Dedicated R&D teams to support client formulation. Proactive problem-solving and process optimization. Joint development programs.	Standard technical support for product specifications. Responds to customer inquiries regarding product attributes.
Lead Time & Flexibility	Predictable lead times (<12 weeks for standard orders). Ability to handle urgent requests or small-to-large batch size variations efficiently.	Standard lead times (12-20 weeks). Less flexibility in accommodating urgent requests or significant batch size changes.
Pricing Strategy	Value-based pricing reflecting quality and service. Tiered pricing for volume commitments.	Competitive pricing based on market benchmarks. Less differentiation in pricing structure.

What Are the Potential Risks and Mitigation Strategies for Sourcing Hexamvinolevulinate Hydrochloride?

Sourcing hexaminolevulinate hydrochloride involves inherent risks that can impact supply continuity, product quality, and regulatory compliance. Effective mitigation strategies are essential.

Key Risks:

• Supply Chain Disruptions: Dependence on single suppliers for raw materials or intermediates, geopolitical instability, natural disasters, or unexpected production outages can halt manufacturing.
• Quality Control Failures: Batch-to-batch variability, presence of uncharacterized impurities, or deviations from GMP can lead to product rejection, recalls, and regulatory action.
• Regulatory Non-Compliance: Changes in regulatory requirements, failed inspections, or inadequate documentation can result in delays or the inability to market the drug.
• Intellectual Property Issues: Reliance on suppliers who may infringe on existing patents can lead to legal challenges.
• Counterfeit or Substandard Products: The risk of unknowingly procuring materials from unreliable sources that do not meet specifications.
• Capacity Constraints: Suppliers unable to scale production to meet increasing demand can lead to shortages.

Mitigation Strategies:

• Supplier Qualification and Auditing: Implement a rigorous supplier qualification program that includes thorough audits of manufacturing facilities, quality systems, and regulatory compliance.
• Dual Sourcing and Geographic Diversification: Identify and qualify multiple suppliers for critical raw materials and the API itself, ideally located in different geographic regions to mitigate regional risks.
• Robust Quality Agreements: Establish comprehensive quality agreements with suppliers that clearly define specifications, testing protocols, change control procedures, and responsibilities.
• Contingency Planning: Develop contingency plans for supply disruptions, including pre-identified alternative suppliers and stock management strategies.
• Proactive Regulatory Monitoring: Stay informed about evolving regulatory requirements in key markets and engage with suppliers to ensure their compliance.
• Intellectual Property Due Diligence: Conduct IP landscape analysis and ensure that suppliers have the necessary rights to manufacture and supply the API.
• Regular Performance Monitoring: Continuously monitor supplier performance against agreed-upon metrics, including quality, delivery times, and responsiveness.
• Building Strong Relationships: Foster collaborative relationships with key suppliers, promoting transparency and open communication regarding potential challenges.

Table 5: Risk Assessment and Mitigation for Hexamvinolevulinate Hydrochloride Sourcing

Risk Category	Specific Risk	Likelihood	Impact	Mitigation Strategy
Supply Chain	Dependence on single raw material supplier for a key precursor.	Medium	High	Dual sourcing of critical raw materials. Supplier audits focusing on their raw material sourcing. Maintaining strategic inventory of key intermediates.
	Geopolitical instability in a supplier's region impacting production or logistics.	Low	High	Geographic diversification of manufacturing sites. Regular geopolitical risk assessments for key supplier locations. Contingency plans for rerouting logistics.
Quality Control	Batch-to-batch variability in API purity or critical impurity levels.	Medium	High	Strict adherence to validated manufacturing processes. Enhanced in-process controls. Comprehensive final product testing with clear acceptance criteria. Detailed Certificates of Analysis.
	Discovery of a new, uncharacterized impurity post-approval.	Low	Very High	Robust impurity profiling during development. Ongoing stability studies. Proactive engagement with suppliers on process understanding and potential degradation pathways.
Regulatory	Supplier facility failing a GMP inspection.	Medium	High	Thorough pre-qualification audits. Regular follow-up audits. Verification of supplier's internal audit schedules and CAPA effectiveness.
	Changes in pharmacopoeial standards or regulatory guidelines requiring process modifications.	Medium	Medium	Continuous monitoring of regulatory updates and pharmacopoeial revisions. Close collaboration with suppliers on process development and validation for compliance.
Intellectual Property	Supplier using a process that infringes on third-party patents.	Low	Very High	Thorough IP due diligence during supplier selection. Request for IP indemnity clauses in supply agreements.
Capacity	Supplier unable to increase output to meet demand from new clinical trials or market penetration.	Medium	High	Capacity planning discussions with suppliers. Qualification of secondary or tertiary suppliers. Developing in-house capabilities for critical intermediates if feasible.

Key Takeaways

• The supply landscape for hexaminolevulinate hydrochloride is characterized by a mix of large pharmaceutical companies overseeing integrated supply chains and specialized API manufacturers.
• Regulatory compliance, particularly GMP adherence, is non-negotiable and a primary determinant of supplier suitability.
• Production capacity and scalability are key considerations for ensuring supply chain resilience, with established API manufacturers generally offering higher potential for expansion.
• Supplier differentiation hinges on API quality, regulatory track record, manufacturing robustness, and technical support.
• Sourcing risks, including supply chain disruptions and quality failures, necessitate robust mitigation strategies such as dual sourcing, rigorous auditing, and comprehensive quality agreements.

Frequently Asked Questions

1. What is the typical lead time for ordering hexaminolevulinate hydrochloride API from a qualified supplier? Lead times can vary but generally range from 12 to 20 weeks for standard orders from qualified GMP manufacturers, depending on batch size and supplier current production schedules. Expedited orders may be possible with additional cost and negotiation.

2. Are there any generic versions of hexaminolevulinate hydrochloride available, and how does this affect supplier choice? While Gleolan is a branded product, the availability of generic versions of the API would broaden the supplier base and potentially increase price competition. Pharmaceutical companies developing generic hexaminolevulinate hydrochloride treatments would need to qualify suppliers meeting specific regulatory and quality standards for API production.

3. What analytical methods are critical for ensuring the quality of hexaminolevulinate hydrochloride? Critical analytical methods include High-Performance Liquid Chromatography (HPLC) for purity and impurity profiling, Mass Spectrometry (MS) for structural confirmation, Nuclear Magnetic Resonance (NMR) for structural elucidation, and Karl Fischer titration for water content.

4. How does the intended use of hexaminolevulinate hydrochloride in photodynamic therapy influence supplier selection criteria? Its use in photodynamic therapy, particularly for oncological applications, demands extremely high purity and a well-defined impurity profile to ensure patient safety and treatment efficacy. Suppliers must demonstrate robust control over potentially photosensitive impurities.

5. What are the implications of a supplier's intellectual property position regarding the synthesis of hexaminolevulinate hydrochloride? Suppliers must demonstrate they have the legal right to manufacture and supply the API. This involves ensuring their synthetic routes do not infringe on existing patents. Pharmaceutical companies sourcing the API should conduct due diligence to avoid potential IP disputes.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP) | FDA. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-compliance/good-manufacturing-practice-gmp [2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/compliance-regulation/good-manufacturing-practice [3] Pharmaceuticals and Medical Devices Agency. (n.d.). GMP Compliance. Retrieved from https://www.pmda.go.jp/english/jd-compliance/gdpr/0005.html [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/ich-guidelines [5] United States Pharmacopeia. (n.d.). Pharmacopeial Information. Retrieved from https://www.usp.org/products-services/pharmacopeial-information [6] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia-ph-eu